IQV · Iqvia Holdings Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.15B | - | $4.10B | $4.02B | $3.83B | - | $3.90B | $3.81B | $3.74B | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | $915.00M | $863.00M | $827.00M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $502.00M | - | $514.00M | $509.00M | $508.00M | - | $522.00M | $509.00M | $508.00M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $288.00M | - | $286.00M | $276.00M | $265.00M | - | $278.00M | $269.00M | $264.00M | - |
| Operating Income | $514.00M | - | $553.00M | $506.00M | $496.00M | - | $550.00M | $520.00M | $506.00M | - |
| Interest Expense | $192.00M | - | $189.00M | $182.00M | $165.00M | - | $170.00M | $163.00M | $166.00M | - |
| Income Tax | $59.00M | - | $76.00M | $56.00M | $61.00M | - | $65.00M | $75.00M | $49.00M | - |
| Net Income | $274.00M | - | $331.00M | $266.00M | $249.00M | - | $285.00M | $363.00M | $288.00M | - |
| EPS - Basic | $1.63 | - | $1.94 | $1.55 | $1.42 | - | $1.57 | $1.99 | $1.58 | - |
| EPS - Diluted | $1.61 | - | $1.93 | $1.54 | $1.40 | - | $1.55 | $1.97 | $1.56 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.95B | $1.98B | $1.81B | $2.04B | $1.74B | $1.70B | $1.57B | $1.54B | $1.44B | $1.38B |
| Accounts Receivable | $3.35B | $3.40B | $3.27B | $3.34B | $3.27B | $3.20B | $3.20B | $3.25B | $3.43B | $3.38B |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $6.22B | $6.25B | $5.98B | $6.34B | $5.91B | $5.83B | $5.63B | $5.62B | $5.65B | $5.60B |
| Total Assets | $29.68B | $29.94B | $28.73B | $28.63B | $27.32B | $26.90B | $27.18B | $26.40B | $26.57B | $26.68B |
| Current Liabilities | $8.33B | $8.34B | $8.51B | $7.57B | $7.18B | $6.96B | $6.99B | $6.62B | $6.45B | $6.49B |
| Long-term Debt | $13.99B | $13.88B | $12.79B | $14.18B | $13.11B | $12.84B | $12.29B | $12.09B | $12.82B | $12.96B |
| Total Liabilities | $23.33B | $23.31B | $22.44B | $22.85B | $21.34B | $20.83B | $20.21B | $19.68B | $20.23B | $20.57B |
| Stockholders' Equity | $6.22B | $6.50B | $6.16B | $5.78B | $6.07B | $6.07B | $6.97B | $6.71B | $6.34B | $6.11B |
| Retained Earnings | $7.70B | $7.42B | $6.91B | $6.58B | $6.31B | $6.07B | $5.63B | $5.34B | $4.98B | $4.69B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $618.00M | - | - | - | $568.00M | - | - | - | $522.00M | - |
| Investing Cash Flow | ($196.00M) | - | - | - | ($305.00M) | - | - | - | ($314.00M) | - |
| Financing Cash Flow | ($433.00M) | - | - | - | ($258.00M) | - | - | - | ($106.00M) | - |
| CapEx | $127.00M | - | - | - | $142.00M | - | - | - | $145.00M | - |
| Free Cash Flow | $491.00M | - | - | - | $426.00M | - | - | - | $377.00M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | 23.5% | 22.6% | 22.1% | - |
| Operating margin | 12.4% | - | 13.5% | 12.6% | 13.0% | - | 14.1% | 13.6% | 13.5% | - |
| EBITDA margin | 19.3% | - | 20.5% | 19.5% | 19.9% | - | 21.3% | 20.7% | 20.6% | - |
| Net margin | 6.6% | - | 8.1% | 6.6% | 6.5% | - | 7.3% | 9.5% | 7.7% | - |
| Free cash flow margin | 11.8% | - | - | - | 11.1% | - | - | - | 10.1% | - |
| FCF / Net income | 1.79 | - | - | - | 1.71 | - | - | - | 1.31 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 12.1% | - | 12.5% | 12.7% | 13.3% | - | 13.4% | 13.3% | 13.6% | - |
| Effective tax rate | 17.7% | - | 18.7% | 17.4% | 19.7% | - | 18.6% | 17.1% | 14.5% | - |
| Return on assets | 0.9% | - | 1.2% | 0.9% | 0.9% | - | 1.0% | 1.4% | 1.1% | - |
| Return on equity | 4.4% | - | 5.4% | 4.6% | 4.1% | - | 4.1% | 5.4% | 4.5% | - |
| Return on invested capital | 2.1% | - | 2.4% | 2.1% | 2.1% | - | 2.3% | 2.3% | 2.3% | - |
| Liquidity | ||||||||||
| Current ratio | 0.75 | 0.75 | 0.70 | 0.84 | 0.82 | 0.84 | 0.81 | 0.85 | 0.88 | 0.86 |
| Quick ratio | 0.75 | 0.75 | 0.70 | 0.84 | 0.82 | 0.84 | 0.81 | 0.85 | 0.88 | 0.86 |
| Cash ratio | 0.23 | 0.24 | 0.21 | 0.27 | 0.24 | 0.24 | 0.22 | 0.23 | 0.22 | 0.21 |
| Leverage | ||||||||||
| Debt / Equity | 2.25 | 2.14 | 2.08 | 2.45 | 2.16 | 2.12 | 1.76 | 1.80 | 2.02 | 2.12 |
| Debt / Assets | 0.47 | 0.46 | 0.45 | 0.50 | 0.48 | 0.48 | 0.45 | 0.46 | 0.48 | 0.49 |
| Debt / EBITDA | 17.44 | - | 15.25 | 18.13 | 17.22 | - | 14.85 | 15.32 | 16.65 | - |
| Interest coverage | 2.7x | - | 2.9x | 2.8x | 3.0x | - | 3.2x | 3.2x | 3.0x | - |
| Equity multiplier | 4.77 | 4.60 | 4.66 | 4.96 | 4.50 | 4.43 | 3.90 | 3.93 | 4.19 | 4.37 |
| Liabilities / Assets | 0.79 | 0.78 | 0.78 | 0.80 | 0.78 | 0.77 | 0.74 | 0.75 | 0.76 | 0.77 |
| Efficiency | ||||||||||
| Asset turnover | 0.14 | - | 0.14 | 0.14 | 0.14 | - | 0.14 | 0.14 | 0.14 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 294d | - | 291d | 304d | 312d | - | 299d | 312d | 335d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 105.9x | - | 98.4x | 102.3x | 125.9x | - | 152.9x | 107.3x | 162.1x | - |
| P / B | 4.7x | - | 5.3x | 4.7x | 5.2x | - | 6.3x | 5.8x | 7.3x | - |
| P / S | 7.0x | - | 8.0x | 6.8x | 8.2x | - | 11.2x | 10.2x | 12.5x | - |
| EV / EBITDA | 51.1x | - | 52.0x | 50.4x | 56.0x | - | 65.7x | 62.8x | 75.3x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 8.4% | - | 5.2% | 5.3% | 2.5% | - | 4.3% | 2.3% | 2.3% | - |
| Revenue CAGR (3y) | 4.4% | - | 4.8% | 4.3% | 2.4% | - | 4.7% | 3.5% | 3.1% | - |
| Revenue CAGR (5y) | 4.0% | - | 8.0% | 9.8% | 6.8% | - | 7.1% | 6.8% | 6.8% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | 6.1% | 1.5% | 3.1% | - |
| Operating income growth (YoY) | 3.6% | - | 0.5% | -2.7% | -2.0% | - | 14.3% | -0.8% | 7.4% | - |
| Net income growth (YoY) | 10.0% | - | 16.1% | -26.7% | -13.5% | - | -5.9% | 22.2% | -0.3% | - |
| EPS growth (YoY) | 15.0% | - | 24.5% | -21.8% | -10.3% | - | -4.9% | 23.9% | 2.0% | - |
| EPS CAGR (3y) | 1.7% | - | 9.0% | 4.7% | -5.9% | - | 5.0% | 29.8% | 12.7% | - |
| EPS CAGR (5y) | 8.1% | - | 30.0% | - | 27.2% | - | 39.8% | 45.7% | 40.0% | - |
| FCF growth (YoY) | 15.3% | - | - | - | 13.0% | - | - | - | 49.0% | - |
| FCF CAGR (5y) | -7.3% | - | - | - | 80.9% | - | - | - | 55.9% | - |
| Book value growth (YoY) | 2.5% | 7.2% | -11.6% | -13.9% | -4.4% | -0.7% | 20.0% | 16.8% | 6.9% | 6.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$16.31B totalResearch And Development Solutions$8.90B · 54.5%
Technology And Analytics Solutions$6.63B · 40.6%
Contract Sales And Medical Solutions$788.00M · 4.8%
Geographic
$6.63B totalAmericas$3.36B · 50.8%
EMEA$2.65B · 39.9%
Asia Pacific$617.00M · 9.3%
Peer comparison
Same SIC group: Services-Commercial Physical & Biological Research
Comparing IQVIA HOLDINGS INC. against the 5 most active filers in the same SIC group.